Global Anemia Treatment Market size is expected to be worth around USD 19.1 Billion by 2033, from USD 9.7 Billion in 2023, growing at a CAGR of 7.2% Lawrence John Prudour +91 91308 55334 ...

An unusual swelling in the legs and feet could indicate the onset of kidney damage. When the kidneys struggle to eliminate ...

Chronic kidney disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia or pericarditis. There is no specific treatment ...

Anemia is common in patients who have both heart failure and chronic kidney disease, and there is an association between anemia and progression of both diseases. The main causes of anemia are ...

Iron deficiency may be linked to non-dialysis-dependent chronic kidney disease and mortality in patients without anemia, according to results of a nationwide cohort study. Overall, 27.2% of ...

Anemia is highly prevalent in patients with ... human erythropoietin therapy in anemic patients with chronic kidney disease and concomitant heart disease have demonstrated a reduction in left ...

In this study, both anemia and chronic kidney disease were highly prevalent among HF patients discharged from two university hospitals and independently associated with an increased risk of dying ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

Dr Ravinder K Gupta, Dr Akhilpreet Kaur Anemia is a serious global public health problem that particularly affects young ...